<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://peptidebureau.com/lilly-hims-hers-zepbound-foundayo-agreement.html</loc>
    <news:news>
      <news:publication><news:name>Peptide Bureau</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-08T01:17:00+00:00</news:publication_date>
      <news:title>Hims &amp; Hers Will Offer Lilly&#x27;s Zepbound and Foundayo at Lilly&#x27;s Self-Pay Prices, and Says It Will Not Sell Compounded Copies</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidebureau.com/fda-warning-letter-ronanrx-american-made-compounded-glp-1.html</loc>
    <news:news>
      <news:publication><news:name>Peptide Bureau</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-08T01:09:00+00:00</news:publication_date>
      <news:title>FDA Warns RonanRx Over &#x27;American Made&#x27; Compounded Semaglutide and Tirzepatide, Saying No U.S. Plant Is Listed as the Drug Substance Maker</news:title>
    </news:news>
  </url>
</urlset>
